Success Metrics

Clinical Success Rate
90.7%

Based on 49 completed trials

Completion Rate
91%(49/54)
Active Trials
5(8%)
Results Posted
45%(22 trials)
Terminated
5(8%)

Phase Distribution

Ph phase_2
24
37%
Ph not_applicable
8
12%
Ph phase_1
16
25%
Ph phase_3
9
14%
Ph phase_4
7
11%

Phase Distribution

16

Early Stage

24

Mid Stage

16

Late Stage

Phase Distribution64 total trials
Phase 1Safety & dosage
16(25.0%)
Phase 2Efficacy & side effects
24(37.5%)
Phase 3Large-scale testing
9(14.1%)
Phase 4Post-market surveillance
7(10.9%)
N/ANon-phased studies
8(12.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

87.5%

49 of 56 finished

Non-Completion Rate

12.5%

7 ended early

Currently Active

5

trials recruiting

Total Trials

65

all time

Status Distribution
Active(6)
Completed(49)
Terminated(7)
Other(3)

Detailed Status

Completed49
Terminated5
unknown3
Recruiting3
Active, not recruiting2
Withdrawn2

Development Timeline

Analytics

Development Status

Total Trials
65
Active
5
Success Rate
90.7%
Most Advanced
Phase 4

Trials by Phase

Phase 116 (25.0%)
Phase 224 (37.5%)
Phase 39 (14.1%)
Phase 47 (10.9%)
N/A8 (12.5%)

Trials by Status

active_not_recruiting23%
unknown35%
completed4975%
recruiting35%
terminated58%
enrolling_by_invitation12%
withdrawn23%

Recent Activity

Clinical Trials (65)

Showing 20 of 65 trialsScroll for more
NCT05468619Phase 1

Neonatal Phase 1 Valacyclovir Study

Completed
NCT05446571Phase 3

Prenatal Treatment of Congenital Cytomegalovirus Infection With Letermovir Versus Valaciclovir

Recruiting
NCT06914479Phase 1

Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and Young Adult Patients With Resectable, Recurrent Primary Malignant Brain Tumors

Recruiting
NCT00492050Phase 2

Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia

Active Not Recruiting
NCT05536349Phase 2

Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)

Recruiting
NCT07363031Phase 2

Oral Herpesviruses and Oral Mucositis in Patients Receiving Head and Neck Radiotherapy

Enrolling By Invitation
NCT03282916Phase 2

Anti-viral Therapy in Alzheimer's Disease

Completed
NCT02768363Phase 2

Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)

Active Not Recruiting
NCT04448392Phase 1

Valacyclovir in Neonatal Herpes Simplex Virus Disease

Completed
NCT07014397Not Applicable

Effect of Valaciclovir on Inter-Appointment Pain in Endodontic Treatment of Necrotic Teeth

Completed
NCT03576612Phase 1

GMCI, Nivolumab, and Radiation Therapy in Treating Patients With Newly Diagnosed High-Grade Gliomas

Completed
NCT03004183Phase 2

SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC

Completed
NCT01149460Phase 1

Valacyclovir 1000 mg Tablet Under Fed Conditions

Completed
NCT00589875Phase 2

Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma

Completed
NCT05492591Phase 2

A Study Exploring Efficacy of Peginterferon in Patients With Herpes Zoster

Completed
NCT02831933Phase 2

Trial of Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma and Uveal Melanoma

Terminated
NCT00634231Phase 1

A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors

Completed
NCT00751270Phase 1

Phase 1b Study of AdV-tk + Valacyclovir Combined With Radiation Therapy for Malignant Gliomas

Completed
NCT00638612Phase 1

AdV-tk Therapy With Surgery and Chemoradiation for Pancreas Cancer (PaTK01)

Completed
NCT01658826Phase 2

Safety and Efficacy Comparator Trial of a New Drug Against Genital Herpes

Terminated

Drug Details

Intervention Type
DRUG
Total Trials
65